Corient Private Wealth LLC Has $2.60 Million Stock Position in Sana Biotechnology, Inc. $SANA

Corient Private Wealth LLC reduced its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 21.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 638,367 shares of the company’s stock after selling 178,633 shares during the quarter. Corient Private Wealth LLC’s holdings in Sana Biotechnology were worth $2,598,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. LRI Investments LLC bought a new stake in shares of Sana Biotechnology during the fourth quarter worth approximately $41,000. Jacobi Capital Management LLC bought a new position in shares of Sana Biotechnology during the fourth quarter worth approximately $41,000. Mercer Global Advisors Inc. ADV acquired a new stake in Sana Biotechnology during the 3rd quarter worth approximately $36,000. Foguth Wealth Management LLC. acquired a new stake in Sana Biotechnology during the 4th quarter worth approximately $44,000. Finally, Cibc World Markets Corp bought a new stake in Sana Biotechnology in the 4th quarter valued at $44,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SANA has been the topic of a number of research reports. Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wedbush boosted their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Sunday, June 7th. Finally, Morgan Stanley restated an “overweight” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research note on Friday, March 13th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Stock Performance

NASDAQ SANA opened at $3.42 on Monday. The company has a market cap of $951.75 million, a price-to-earnings ratio of -3.68 and a beta of 2.14. The company has a 50 day moving average of $3.20 and a 200-day moving average of $3.71. Sana Biotechnology, Inc. has a 1-year low of $2.60 and a 1-year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.